FEMASYS INC Annual Report - How They Did This Year

I’m breaking down Femasys Inc.’s latest performance to help you decide if this company fits your investment strategy.

1. What does this company do?

Femasys creates medical technology for women’s health. They design in-office tools for fertility and permanent birth control, aiming to replace hospital-based, invasive surgeries with simpler, non-surgical alternatives. They use a "razor-and-blade" business model: they sell the delivery devices and the required kits for each procedure.

2. Major Wins: Products and Global Reach

The company is successfully moving from development to the market:

• FemaSeed: This fertility tool delivers sperm directly to the site of conception. It is FDA-cleared in the U.S. and approved in the UK, Canada, and Australia. They recently partnered with major centers like Boston IVF and HRC Fertility to encourage doctors to use it. FemaSeed is in the early stages of sales, bringing in about $0.3 million in annual revenue.
• FemBloc: This is their permanent birth control system. In 2025, they received regulatory approval in the EU, UK, and New Zealand. In the U.S., they are finishing the final clinical trial needed for FDA approval. Success here is vital, as the U.S. market for permanent birth control is worth hundreds of millions of dollars annually.

3. Financial Health: The "Going Concern" Warning

This is the most important section for you. Femasys is still spending heavily. For the year ending December 31, 2023, they lost $17.8 million, compared to $16.5 million the year before. They warned investors there is "substantial doubt" about their ability to stay in business.

They are burning through cash—roughly $1.2 million to $1.5 million monthly—to fund trials and sales teams. By year-end, they had about $6.8 million in cash. They must raise more money soon, likely by issuing more shares, which reduces your ownership percentage. Additionally, they have faced challenges keeping their stock price above the $1.00 minimum required by NASDAQ.

4. Key Risks: What could go wrong?

• The Cash Crunch: Their spending exceeds their cash. If they cannot raise more money, they may have to stop operations.
• Regulatory Hurdles: The FDA approval process for FemBloc is complex. Any delays or requests for more data could push the U.S. launch back and increase costs.
• Adoption Risk: They must secure insurance coverage codes. Without insurance, patients must pay out-of-pocket, which limits widespread use.
• Supply Chain: They rely on a few outside manufacturers. If these partners have problems or fail quality checks, Femasys cannot fulfill orders.

Investor Takeaway

Femasys is a high-risk, high-reward investment. They hold over 175 patents and have cleared international regulatory hurdles. However, they are currently operating with limited cash reserves. Their survival depends on finishing U.S. clinical trials and securing insurance coverage. Before investing, consider whether you are comfortable with the risk of potential share dilution and the company's need for immediate additional funding to maintain operations.